Prostaatkanker
Hulpbronnen en materialen
Klinische studies
PROfound
Professor Lumen en dr De Maeseneer bespreken de resultaten van de PROfound trial en wat de terugbetaling betekent voor uw patiënten
MoA en genetische testing
Gedetailleerde infographic omtrent genetische testing
Educational videos
Prof. Dr. Sautois on PROfound trial: clinical results
Dr. De Putter on germline genetic testing in prostate cancer
Prof. Dr. Pauwels on the failure rate for tissue BRCA testing in clinical practice
Prof. Dr. Pauwels on what we learned from the PROfound trial
'Dr. De Putter on why we should do a tissue test after a negative germline test
Voor patiënten
Dagboek voor Lynparza patiënten
Evenementen
Momenteel zijn er geen evenementen.
Referenties
1. LYNPARZA® 100 mg and 150 mg tabletten, samenvatting van de productkenmerken, meest recente versie
2. https://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/nl/Public/ProductSearch (accès 25/10/2021)
3. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015; 60(4):547–560.
4. Lord CJ and Ashworth A. PARP inhibitors: The first synthetic lethal targeted therapy. Science. 2017;355(6330):1152–1158.
5. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer . N Engl J Med. 2020;382(22):2091–2102.
6. de Bono J et al. Poster 847PD. Central, prospective detection of homologous recombination repair gene alterations in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer screened for the PROfound study. Presented at: ESMO Annual Meeting; 27 September-1 October, 2019; Barcelona, Spain.
7. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. Supplementary appendix.
8. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. Protocol.
9. de Bono J et al. Central, prospective detection of homologous recombination repair gene alterations in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer screened for the PROfound study. Poster 847PD. Presented at ESMO Annual Meeting, 27 September–1 October 2019, Barcelona, Spain.
10. Hussain M et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020. doi: 10.1056/NEJMoa2022485.
11. Parker C et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134.
12. Cheng HH et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw. 2019;17(5):515– 521.
13. Abida W et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Onco. 2017. doi: 10.1200/PO.17.00029